Trump to dedicate $500M over 10 years to childhood cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In his State of the Union address Feb. 5, President Donald Trump said he plans to ask Congress for $500 million over 10 years to fund pediatric cancer research—an amount Speaker of the House Nancy Pelosi (D-CA) said is insufficient.

“Many childhood cancers have not seen new therapies in decades,” Trump said. “My [president’s] budget [proposal] will ask the Congress for $500 million over the next 10 years to fund this critical life-saving research.”

According to Politico, Pelosi said in a closed-door conference meeting, “$500 million over 10 years—are you kidding me? Who gave him that [$50 million] figure? It’s like the cost of his protection of his Mar-a-Lago or something.”

At the same meeting, Pelosi called Trump’s proposal a “trolley ride” when compared to the Beau Biden Cancer Moonshot.

“We’re talking about a moonshot,” Pelosi said during the conference meeting Feb. 6, according to Politico. “He’s talking about a trolley ride.”

In December 2016, Congress authorized $1.8 billion over seven years for then Vice President Joe Biden’s National Cancer Moonshot Initiative (The Cancer Letter, Dec. 16, 2016).

Trump’s plan would allocate $50 million per year for childhood cancer research. For perspective, the Cancer Moonshot receives about $257 million a year when averaged over seven years (The Cancer Letter, To the Moon).

“Tonight, I am also asking you to join me in another fight that all Americans can get behind: the fight against childhood cancer,” Trump said in his address. “Joining Melania in the gallery this evening is a very brave 10-year-old girl, Grace Eline. Every birthday since she was four, Grace asked her friends to donate to St. Jude Children’s Research Hospital.

“She did not know that one day she might be a patient herself. Last year, Grace was diagnosed with brain cancer,” Trump said. “Immediately, she began radiation treatment. At the same time, she rallied her community and raised more than $40,000 for the fight against cancer. When Grace completed treatment last fall, her doctors and nurses cheered with tears in their eyes as she hung up a poster that read: ‘Last Day of Chemo.’ Grace—you are an inspiration to us all.”

Nancy Goodman, founder and executive director of Kids v Cancer, an advocacy group, said Trump’s speech and Pelosi’s comment, though at odds with each other, signal intent to find new money for research in pediatric cancer.

“President Trump, Speaker Pelosi, put your money where your mouth is and appropriate more than half a billion dollars to have scientists develop some cures for kids with cancer,” Goodman said to The Cancer Letter. “It’s clear from President Trump’s statement and Speaker Pelosi’s statement that they’re talking about new money. So, let’s be clear about that and appropriate some new funding.”

Claire Dietz
Claire Dietz

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.
Claire Dietz
Claire Dietz

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login